The Biostatistics Core will have a collaborative role in the statistical design, the statistical analysis, and the dissemination of research results for all experimental and clinical studies defined in the project proposals and studies, proposed and awarded, from the Career Development and Research Development Programs for this SPORE on Skin Cancer. The members of this core include three senior biostatisticians who have strong existing collaborations with SPORE investigators, relevant knowledge of biostatistical methods and their application to research proposed in the SPORE, and an extensive publication record that reflect their expertise and collaborations in skin cancer. The Biostatistics Core will provide expertise and experience in three areas. The first is research methodology for study design including population definition, measurement issues, potential bias, sample size and power, randomization and efficient experimental design. The second is statistical methodology for estimation, hypothesis testing and modeling as well as for conducting methodological research to solve practical problems that arise, comparing alternative methodologies and conducting discovery studies that are motivated by for the translational goals of the SPORE research projects. The third area is interpretation and presentation of research data that are supported by scientifically and statistically justified statements for dissemination of knowledge gained from research studies. The Biostatistics Core personnel have established collaborations through one-on-one meetings and project meetings with SPORE investigators. These collaborations have led to 29 publications (2007-2012) that have contributed significantly to our understanding of melanoma.

Public Health Relevance

Collaboration between the senior biostatisticians in the Biostatistics Core and the research investigators conducting SPORE-related studies will insure that the SPORE research studies will have high quality study designs and relevant statistical analysis plans that will provide a solid foundation for each study's conclusions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA174523-01A1
Application #
8664626
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Project Start
Project End
Budget Start
2014-09-15
Budget End
2015-03-31
Support Year
1
Fiscal Year
2014
Total Cost
$249,218
Indirect Cost
$21,250
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Onorati, Angelique V; Dyczynski, Matheus; Ojha, Rani et al. (2018) Targeting autophagy in cancer. Cancer 124:3307-3318
Perego, M; Maurer, M; Wang, J X et al. (2018) A slow-cycling subpopulation of melanoma cells with highly invasive properties. Oncogene 37:302-312
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:
Duperret, Elizabeth K; Trautz, Aspen; Ammons, Dylan et al. (2018) Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice. Clin Cancer Res 24:1190-1201
Hammerlindl, Heinz; Ravindran Menon, Dinoop; Hammerlindl, Sabrina et al. (2018) Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers. Clin Cancer Res 24:1090-1102
Al Emran, Abdullah; Marzese, Diego M; Menon, Dinoop Ravindran et al. (2018) Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget 9:8206-8222
Ecker, Brett L; Kaur, Amanpreet; Douglass, Stephen M et al. (2018) Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis. Cancer Discov :
Sinnamon, Andrew J; Neuwirth, Madalyn G; Gimotty, Phyllis A et al. (2018) Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma. JAMA Oncol 4:126-128
Sarvi, Sana; Crispin, Richard; Lu, Yuting et al. (2018) ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating Cells. Cell Chem Biol 25:1456-1469.e6
Noguera-Ortega, Estela; Amaravadi, Ravi K (2018) Autophagy in the Tumor or in the Host: Which Plays a Greater Supportive Role? Cancer Discov 8:266-268

Showing the most recent 10 out of 89 publications